MAAT PHARMA
Bio & Health (Biotech - Medtech - e/m-Health - Pharma)

One line pitch:
MaaT Pharma (for Microbiota as a Therapy) is proposing a new medical paradigm by developing a series of microbial drugs aiming at restoring the man-microbes symbiosis.

Market Analysis:
The Human Microbiome market is a nascent market expected to reach a one digit billion € (both in therapeutics and diagnostics) within the next decade (first product to be launched by 2018). Market expansion will be driven by progress made on research. MaaT Pharma made the strategic choice to position itself in the segment of hospital-acquired infectious diarrhoea, probably one of the largest segment of this market. Our initial focus is to develop therapeutics in two main domains: Blood cancer (first step: Leukemia) and Infectious disease (first step: Bone Joint Infection). The two sub-segments addressed by MaaT Pharma are estimated to be c. 350 m€ by 2022 on the basis of 100,000 patients treated per year in Europe.

Business Proposition:
MaaT Pharma proposes to correct treatment-induced dysbiosis by delivering a drug aiming at restoring a balanced intestinal ecosystem. Our initial focus will be on providing a platform for safe (autologous; qualified inoculum) and cost effective microbiota restoration made of two main products: MaaT001 (Innovative live frozen inoculum suspension) and MaaT002 (Innovative device for stool collection and storage, convenient for duodenal or rectal administration).

Competitive Advantage:
On the one hand, MaaT Pharma owns a sustainable competitive advantage thanks to its exclusive partnership with INRA (also co-founder) with regard to the fecal microbiota transplantation domain. On the other hand, the company will rely on: - Its unique strategic autologous positioning - The selected initial indications: Leukemia and Bone Joint Infections - The notoriety of its co-founders and advisors - Its close relationship with regulatory bodies - Exceptional non-dilutive funding: 2+ m€ - First venture capital fund focused on investment in the microbiome.

Investment Attractiveness:
MaaT Pharma focuses dysbiosis correction, Technological platform could expand to other therapies launching ramp to with tremendous market potential, Unique autologous niche positioning, Seasoned team with KOL support in the Microbiome space, Clinical phase II completed by end of 2017, High valuation expected, Perfect timing to jump into a highly growing nascent (microbiome) industry.

IP Situation:
MaaT Pharma has a lean patent portfolio focused on its lead drug. As of September 2015, the company already owned two pending patents applications on i) Innovative live frozen inoculum suspension and ii) Innovative device for stool collection and storage, convenient for duodenal or rectal administration.